Precision BioSciences, Inc.

At Precision, we're Dedicated to Improving Life, or #DTIL. Sinu Bhandaru, our Vice President of Operations and IT, shares his journey as a biotech leader and a parent of a child with a rare genetic disease. From discovering the potential of ARCUS to working alongside our brilliant scientists, Sinu’s story highlights why Precision’s focus on safely delivering cures matters now more than ever. His message is one of optimism: “We’re getting closer to life-changing treatments, don’t lose hope.” https://loom.ly/bf_LqrE #GeneEditing #Biotech #DTIL #RareDiseaseDay

Today is #RareDiseaseDay ?? The Precision team is driven to make a difference and stand with the rare disease community, championing innovation and hope. Together, we can change lives. NORD, or the National Organization of Rare Disorders, encourages us all to #ShowYourStripes because, just like a zebra's stripes, every rare individual's journey and story is unique. #DTIL

Initial PBGENE-HBV results are in! Today, Precision BioSciences announced initial safety and antiviral activity of PBGENE-HBV in the ELIMINATE-B Phase 1 dose-finding study for chronic Hepatitis B. This marks the SECOND clinical validation for ARCUS in vivo gene editing in 2025. Listen as CEO, Michael Amoroso, tells you what you need to know. Read our latest press release, https://loom.ly/fHgoJFc #GeneEditing #Biotech #DTIL

Guggenheim hosted the Precision team for a Fireside Chat at its Securities SMID Cap Biotech Conference! Michael Amoroso, Chief Executive Officer, and Cassie Gorsuch, PhD, Chief Scientific Officer, discussed the Company's clinical stage program and expected clinical catalysts in 2025. Webcast link: https://loom.ly/1g8vOFc *A webcast of the presentation will also be accessible on Precision’s website in the Investors section under Events & Presentations at https://loom.ly/UwOZo7s #GeneEditing #Biotech #DTIL

Why are we so passionate about ARCUS? Because it has the potential to be more than just a platform – it could be a game-changer in precision gene editing. ?? Listen as our scientists share what excites them most about ARCUS. From its precision to its potential ability to unlock breakthrough therapies, our team is dedicated to transforming lives through innovation. Want the latest ARCUS news? Visit https://loom.ly/bf_LqrE Or read about the newest developments in our PBGENE-HBV program, https://loom.ly/XFh-clQ Laura Christian Resly, Ph.D Adam Mischler, PhD #GeneEditing #Biotech #DTIL

Precision is thrilled to announce the promotions of Cindy Atwell to Chief Development and Business Officer and Dr. Cassie Gorsuch to Chief Scientific Officer! ?? “I’m delighted to announce the well-deserved promotion of Cindy Atwell who has been instrumental in driving program teams to successful regulatory milestones while also bolstering Precision’s development capabilities through key external partnerships,” said Michael Amoroso, Chief Executive Officer of Precision Biosciences. "Dr. Gorsuch has already established herself as a leader of our company both internally and externally with our various stakeholders," said Dr. Jeff Smith, Co-Founder and Chief Research Officer. "Having Cassie oversee non-clinical development and gene therapy discovery while working alongside me strengthens our capabilities and scientific leadership team." Congratulations to both on these deserved recognitions. To learn more about the promotions and their new roles, visit https://loom.ly/GkiiZqo. #GeneEditing #Biotech #DTIL

Did you see Precision's Head of Gene Discovery Therapy, Cassie Gorsuch, PhD, in Cell & Gene last month? ?? "Precision BioSciences’ Dr. Gorsuch expects in vivo gene editing to make significant strides as more programs advance to the clinic and produce meaningful data. Most will be in rare diseases aimed at delivering a gene knockout to drive a clinical response, but going into large patient populations will be the big advance and potentially transformative for the field." Read the whole article now: https://loom.ly/J7JfRV8 #GeneEditing #Biotech #DTIL

It's been a big week for ARCUS! Precision BioSciences announced a complete clinical response in the first infant dosed by partner iECURE in their ongoing Phase 1/2 Clinical trial in Ornithine Transcarbamylase (OTC) Deficiency. For more information, read our latest press release: https://loom.ly/bf_LqrE Or iECURE's latest press release: https://loom.ly/n1uxiR8 #GeneEditing #Biotech #DTIL

In Hong Kong, where over 400,000 patients are affected by chronic hepatitis B, the unmet need for potentially curative treatments remains a significant public health challenge. MF Yuen, MD, PhD, Chair Professor of Gastroenterology and Hepatology, Li Shu Fan Medical Foundation Professor in Medicine, The University of Hong Kong, shares his thoughts on the recent approval of Precision's Clinical Trial Application in Hong Kong for PBGENE-HBV. To learn more, visit https://loom.ly/XFh-clQ. #HBV #GeneEditing

Did you know that a cancer-causing virus is silently hiding in millions of people worldwide? The New Yorker dove into the global impact of Hepatitis B Virus (HBV) and why it remains a critical health challenge. ?? Read the full article here: https://loom.ly/iQiaAKs At Precision BioSciences, we're working to change the narrative by advancing groundbreaking treatments aimed at potential cures for HBV. Relive the insights from our Investor Day, where we shared the latest on our HBV program and our vision for a world free of chronic HBV. ?? https://loom.ly/WubGrco #HBV #GeneEditing